Overview

Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether spironolactone could significantly reduce cutaneous atrophy due to corticosteroids.
Phase:
Phase 2
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborator:
Société de Dermatologie Française
Treatments:
Clobetasol
Spironolactone